NCT06816953

Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis

Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving Low Dose FVIII Prophylaxis

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 19 (estimated)
• Sponsor: Chulalongkorn University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Patients with severe hemophilia A often develop joint complication requiring careful monitoring. This study aimed to compare the effectiveness of standard low dose weight-based FVIII concentrates (CFCs) prophylaxis with pharmacokinetic-guided extended half-life FVIII concentrates (eHLFVIII) using cartilage biomarkers and HEAD-US score.

Conditions

• Hemophilia A

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	HEAD-US	HEAD-US for evaluate haemophilic arthropathy in 6 joints. (Elbow, Knee, Ankle)
DIAGNOSTIC_TEST	Urinary carboxy-terminal cross linked telopeptide of type II collagen	Cartilage biomarker represent cartilage degradation
DIAGNOSTIC_TEST	Inflammatory markers	Inflammatory markers included CBC, Ferritin, ESR, CRP

Timeline

• Start date: 2024-04-01
• Primary completion: 2025-01-30
• Completion: 2025-02-28
• First posted: 2025-02-10
• Last updated: 2025-02-10

Locations

1 site across 1 country: Thailand